CJC-1295 and blood work: what to test and when

Last updated 2026-07-26

What blood work should you get before starting CJC-1295?

Get a baseline panel before your first injection, not after. Without a baseline you have no way to tell whether a lab value moved because of the peptide or because it was already there. The practical minimum is IGF-1 (also called somatomedin C), fasting glucose, HbA1c, a standard lipid panel, and a metabolic panel that covers kidney and liver markers. If you're working with a prescriber, they may add a pituitary panel (this is a category, not one test: it typically covers thyroid stimulating hormone, cortisol, and sometimes prolactin) since CJC-1295 works upstream of the pituitary gland. IGF-1 is the one number that actually reflects what the peptide is doing. GH itself pulses within minutes and a single blood draw tells you almost nothing about it. The Endocrine Society's clinical practice guideline on growth hormone deficiency testing notes that random GH measurement is not useful diagnostically because of pulsatile secretion, and that stimulation testing or IGF-1 measurement is preferred instead ^[1]. IGF-1, by contrast, stays relatively stable across the day because the liver produces it in response to average GH exposure over time, so it's the more useful single-draw marker. If you have a personal or family history of diabetes, get HbA1c and fasting insulin at baseline too, more than fasting glucose. GH physiology has a known antagonistic relationship with insulin action, and you want a real starting number before you introduce anything that raises GH pulses.

Does CJC-1295 raise IGF-1 levels? What does the research show?

Yes, that's the documented, reproducible effect. The original phase 1/2 study of CJC-1295 (then called modified GRF 1-29 with drug affinity complex, DAC) found that a single injection raised mean plasma GH levels for 6 or more days and produced sustained increases in IGF-1 that lasted up to 9 to 11 days after a single dose, according to the trial published in the Journal of Clinical Endocrinology & Metabolism ^[2]. Multiple dosing over weeks produced IGF-1 increases of roughly 1.5 to 3 times baseline depending on dose, and the effect was durable across the dosing period studied. That's the DAC version, the one with the drug affinity complex that extends its half-life to several days. The no-DAC version (sometimes called CJC-1295 without DAC, or functionally similar to modified GRF 1-29 / tetrasubstituted GRF) has a half-life measured in minutes, not days, so its IGF-1 effect depends entirely on dosing frequency and is far less studied in that specific form. Anyone deciding between the two should read CJC-1295 DAC or no-DAC before assuming the trial data applies equally to both. Outside of that original trial and its follow-up work on the same compound class, there isn't a large published human literature quantifying IGF-1 response to CJC-1295 specifically in the way there is for approved GH therapies. Most of what circulates about exact percentage increases, ideal target ranges for enhancement purposes, or 'optimal' IGF-1 numbers is bodybuilding-forum extrapolation, not published data. Treat any number you see outside that JCEM trial with real skepticism.

How often should you retest IGF-1 while using CJC-1295?

A reasonable retest interval is 4 to 8 weeks after starting, then every 2 to 3 months if you continue. IGF-1 half-life is longer than GH itself but the marker still needs a few weeks of consistent dosing to reflect a new steady state, so testing at 1 or 2 weeks in mostly wastes money. Same-day timing matters less for IGF-1 than for GH, since IGF-1 doesn't pulse the same way. Still, keep it consistent: draw in the morning, fasted, and try to use the same lab each time so you're not comparing across different assay methods. IGF-1 assays vary between manufacturers, and a value from one lab's assay isn't always directly comparable to another's without adjustment, which is part of why endocrine reference ranges are always lab-specific rather than universal. If you stop CJC-1295, IGF-1 should trend back toward baseline as the compound clears. For DAC formulations, that reversal takes longer given the multi-day half-life; for no-DAC, it should move back faster since the compound itself clears in under an hour. If IGF-1 stays elevated well past what the compound's half-life would predict, that's worth flagging to a prescriber, more than to a forum thread.

What should you watch for in glucose and insulin markers?

Fasting glucose, HbA1c, and ideally fasting insulin, checked at baseline and again every few months. This is the panel that matters most for anyone using CJC-1295 for more than a few weeks. Growth hormone has a well-established physiological role in reducing peripheral insulin sensitivity. This is textbook endocrinology, not a peptide-specific side effect. It's the same mechanism behind glucose intolerance seen in acromegaly, a condition of chronic GH excess, and it's why clinical GH replacement therapy in approved settings includes routine glucose monitoring. A GH secretagogue that raises endogenous GH pulses is working on the same axis, even though the magnitude in a healthy adult using modest doses is nowhere near an acromegalic GH output. HbA1c reflects roughly 2 to 3 months of average blood glucose, so it's a better trend marker than a single fasting glucose reading, which can bounce around with the last 24 hours of diet and stress. If HbA1c or fasting insulin creeps up over a few retests, that's a real signal to reconsider dose or frequency, not something to wait out. Anyone with prediabetes, a family history of type 2 diabetes, or existing insulin resistance should treat this panel as non-negotiable rather than optional.

Does CJC-1295 affect cholesterol or lipid panels?

There isn't strong published data specifically on CJC-1295 and lipids, but GH physiology broadly does interact with lipid metabolism, so a standard lipid panel (total cholesterol, LDL, HDL, triglycerides) at baseline and at follow-up is reasonable due diligence. Approved GH replacement therapy literature generally associates adequate GH levels with improved lipid profiles in GH-deficient adults, since GH increases lipolysis and can shift the lipid picture favorably in that specific population. Whether that generalizes to a healthy adult using a GH secretagogue for other reasons isn't established, and it's a meaningfully different starting population. Get the lipid panel because it's cheap. It's already part of most standard blood panels, and there's no downside to having the data. Just don't expect a clean before/after story from it the way you'd get with IGF-1. If your lipid numbers move a lot in either direction, that's more likely explained by diet, exercise change, or other supplements running alongside CJC-1295 than by the peptide itself.

What about thyroid, cortisol, and other pituitary hormones?

A baseline thyroid stimulating hormone (TSH) and morning cortisol are reasonable to include, mostly to rule out a preexisting pituitary or thyroid issue rather than because CJC-1295 is expected to directly suppress them at typical doses. CJC-1295 is a growth hormone releasing hormone (GHRH) analogue. It's designed to act on the GHRH receptor in the pituitary specifically, not on the thyroid or adrenal axes. That specificity is part of the pharmacological rationale in the original CJC-1295 development papers, which describe it as a long-acting GRF (growth hormone releasing factor) analogue engineered for GH-axis selectivity ^[2]. That said, the pituitary is a small gland doing several jobs, and anyone with an existing pituitary lesion, a history of adenoma, or unexplained fatigue, weight change, or menstrual irregularity should get a fuller hormone panel and a conversation with an endocrinologist before starting any GH secretagogue, prescribed or otherwise.

How does CJC-1295 blood work compare to monitoring for prescription GH therapy?

The panels overlap heavily. Recombinant human growth hormone (rhGH) prescribing information and clinical guidelines for adult GH deficiency call for baseline and periodic IGF-1, along with glucose monitoring, precisely because the mechanism (raising GH exposure) is the same axis CJC-1295 targets upstream. The Endocrine Society's clinical practice guideline on adult GH deficiency states that treatment should be monitored with IGF-1 levels, adjusting the dose to keep IGF-1 within the age-adjusted normal range, and that clinicians should also monitor glucose metabolism during treatment ^[3]. | Marker | Prescription GH therapy monitoring | CJC-1295 self-monitoring (reasonable practice) |

Why does CJC-1295 get paired with ipamorelin, and does that change what you monitor?

CJC-1295 is a GHRH analogue; ipamorelin is a ghrelin-receptor agonist (a GH secretagogue in the growth hormone releasing peptide, GHRP, family). They act on two different receptors that both converge on GH release, which is the pharmacological rationale for stacking them: a GHRH analogue increases the amplitude of a GH pulse, and a ghrelin-receptor agonist can trigger a pulse and blunt the somatostatin brake that normally limits it. That mechanistic complementarity is well described in the receptor pharmacology literature on GHRH and ghrelin-receptor signaling. But it's important to be precise about what's actually been shown: there isn't a large published clinical trial specifically testing the CJC-1295 plus ipamorelin combination against either compound alone, with IGF-1 or clinical outcomes as endpoints, in the way there is for CJC-1295/DAC alone ^[2]. The combination is common in practice and the receptor logic is sound, but 'sound mechanism' and 'proven combined outcome' are different claims, and a lot of what's said about the stack's superiority online outruns the actual trial evidence. From a blood work standpoint, the combination doesn't change which markers you check. It just makes IGF-1 the more informative number, since it captures the net downstream effect of both mechanisms rather than requiring you to separate out which compound did what.

Are there blood work red flags that mean you should stop?

Yes. A few results warrant stopping and getting a real medical evaluation rather than waiting for the next scheduled retest. A sharply rising HbA1c or fasting glucose crossing into prediabetic range (HbA1c 5.7-6.4% or fasting glucose 100-125 mg/dL, per the American Diabetes Association's diagnostic criteria) or higher is a stop-and-reassess signal ^[4]. An IGF-1 value climbing well outside the assay's normal reference range for your age and sex is another; IGF-1 reference ranges are age-dependent and drop steadily after young adulthood, so 'high' is relative to your own age bracket, not a single universal number. New or worsening joint pain, carpal tunnel-type numbness or tingling, or unexplained swelling in the hands and feet can accompany elevated GH exposure and are worth a clinical look even if labs seem fine, since symptoms sometimes move faster than a quarterly blood draw catches. Any of these, plus unexplained fatigue, vision changes, or persistent headache (which can, rarely, signal a pituitary issue unrelated to the peptide itself) should prompt stopping and seeing a physician rather than adjusting dose on your own.

How does injection technique or storage affect what shows up in blood work?

Indirectly, but it matters. Inconsistent reconstitution, degraded peptide from poor storage, or injecting into scar tissue or lipohypertrophied areas can all produce inconsistent absorption, which shows up as noisy, hard-to-interpret IGF-1 trends rather than a clean dose-response curve. If your IGF-1 numbers bounce around unpredictably between draws despite a steady dosing schedule, check the basics before assuming something physiological is going on: was the peptide reconstituted correctly and recently, was it stored at the right temperature, and are you rotating injection sites properly? The guides on CJC-1295 reconstitution, CJC-1295 storage and shelf life, and CJC-1295 injection sites cover the practical side of this, and it's worth ruling that out before chasing a physiological explanation for erratic labs.

Where should you get CJC-1295 and have it reviewed by a provider before starting?

Look for a route that includes provider review of your history and labs before you start, more than a checkout page. That's the meaningful difference between a source you can trust with your bloodwork interpretation and one that just ships a vial. CJC-1295 Co works through a provider-reviewed pathway where a clinician looks at your intake and relevant history before anything ships, with fulfillment handled by a licensed pharmacy partner rather than the brand compounding or manufacturing anything itself. If you're deciding between sourcing routes generally, CJC-1295 for sale lays out what a legitimate route looks like, and how to get CJC-1295 walks through the process end to end, including where blood work fits into that intake.

Frequently asked questions

What is the most important blood test to run with CJC-1295?

IGF-1 (somatomedin C) is the single most useful marker, since it reflects average GH exposure over roughly the past 24 hours rather than a single pulse. Pair it with fasting glucose and HbA1c, since GH physiology affects insulin sensitivity and that combination catches the two things most likely to actually change.

How long after starting CJC-1295 should you wait before the first retest?

Four to eight weeks is a reasonable first retest window for IGF-1. Testing sooner than 2 weeks in usually just measures noise rather than a real steady-state change, since IGF-1 needs sustained GH exposure to shift meaningfully.

Does CJC-1295 show up on a standard drug test?

No, standard workplace or medical drug panels test for drugs of abuse and specific medications, not peptide hormones like CJC-1295. It would not appear on a routine urine or blood drug screen; detecting it requires a specific peptide assay that isn't part of standard testing panels.

Can blood work tell the difference between CJC-1295 with DAC and without DAC?

Not directly by looking at IGF-1 alone, since both raise it through the same downstream pathway. The difference shows in the duration and pattern of elevation: DAC's multi-day half-life produces a sustained IGF-1 elevation, while no-DAC's short half-life means IGF-1 tracks much more closely with dosing frequency.

Is a high IGF-1 level dangerous?

It depends on how high and for how long. Chronically very elevated IGF-1, the kind seen in acromegaly, is associated with cardiovascular and metabolic risk over years. A moderate, monitored elevation from short-term GH secretagogue use is a different risk profile, but there's no established 'safe enhancement' upper limit in the literature, so staying within or near your age-adjusted reference range is the more defensible target.

Should you get blood work even if you feel fine on CJC-1295?

Yes. Insulin sensitivity changes and IGF-1 elevation don't reliably produce symptoms you'd notice day to day, especially early on. Feeling fine tells you very little about your glucose trend or IGF-1 trajectory; that's exactly why the labs exist instead of relying on how you feel.

What fasting glucose or HbA1c number should trigger concern?

The American Diabetes Association defines prediabetes as fasting glucose of 100-125 mg/dL or HbA1c of 5.7-6.4%, with diabetes at or above 126 mg/dL fasting or 6.5% HbA1c. Crossing into either range while using a GH secretagogue is a reasonable point to pause and get a full evaluation.

Does ipamorelin need separate blood monitoring from CJC-1295?

No separate panel is needed. Since both act on the same GH-IGF-1 axis through different receptors, IGF-1 captures their combined downstream effect, and the same glucose and lipid monitoring applies whether you're using CJC-1295 alone or paired with ipamorelin.

Can a home fingerstick test replace a lab draw for monitoring?

Fingerstick glucose meters can supplement day-to-day glucose tracking, but IGF-1 and HbA1c require a lab-processed blood draw; there's no reliable at-home equivalent for IGF-1 currently available to consumers.

How much does IGF-1 blood testing typically cost?

Costs vary by lab and whether insurance covers it, but direct-to-consumer IGF-1 panels commonly run somewhere in the $60 to $150 range without insurance, with full panels including glucose and lipids costing more depending on what's bundled.

Will stopping CJC-1295 bring IGF-1 back to baseline?

Generally yes, though the timeline depends on the formulation. No-DAC CJC-1295 clears within about an hour, so IGF-1 should normalize over roughly the following weeks; DAC's multi-day half-life means the elevated IGF-1 signal can take longer to fully resolve after stopping.

Should you tell your regular doctor you're using CJC-1295 before routine blood work?

Yes. Telling your doctor helps them interpret an elevated IGF-1 or glucose trend correctly instead of chasing the wrong diagnosis, and it lets them flag any interaction with existing conditions like diabetes or a pituitary history that changes the risk picture.

Sources

1. Endocrine Society, Evaluation and Treatment of Adult Growth Hormone Deficiency: Clinical Practice Guideline, J Clin Endocrinol Metab 2019, PMID 30982941: GH testing typically relies on stimulation testing rather than a single random draw because GH secretion is pulsatile
2. Journal of Clinical Endocrinology & Metabolism, CJC-1295 phase 1/2 trial: single CJC-1295/DAC injection raised GH for 6+ days and IGF-1 for up to 9-11 days; multi-dose IGF-1 increases of ~1.5-3x baseline
3. Endocrine Society, Clinical Practice Guideline on GH Deficiency in Adults, J Clin Endocrinol Metab 2019: IGF-1 monitoring cadence during GH replacement titration, dosing adjusted to keep IGF-1 in age-adjusted normal range, glucose metabolism monitored during treatment
4. American Diabetes Association, Standards of Care in Diabetes 2024: diagnostic thresholds for prediabetes and diabetes via fasting glucose and HbA1c
5. Katznelson L, et al., Acromegaly: An Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab 2014, PMID 25356808: chronic GH excess in acromegaly is associated with glucose intolerance and metabolic risk